NEW YORK, Sept. 5 — Geneva Bioinformatics, the commercial arm of the Swiss Institute of Bioinformatics (SIB), said on Tuesday it had obtained the rights to exclusively distribute GlycoSuite, Proteome Systems’ database of protein glycosylation.

Glycosylation is a variety of protein modifications important in protein function and diseases such as cancer.

“A significant problem was that information concerning glycosylation was scattered throughout the literature in thousands of scientific publications,” said Proteome Systems CEO Keith Williams in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.